Acute Promyelocytic Leukemia (APL) with PML::RARA fusion — Disease Characteristics Research Report

Target disease: Acute promyelocytic leukemia (APL) driven by the PML::RARA fusion (canonical t(15;17)).
Category: Genetically defined subtype of acute myeloid leukemia (AML). (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Table: This table condenses the core disease-definition, molecular, epidemiologic, identifier, and complication facts for acute promyelocytic leukemia with PML::RARA. It is useful as a quick-reference artifact for populating disease knowledge-base summary fields.

1. Disease information

Overview (what is the disease?)

Acute promyelocytic leukemia (APL) is an AML subtype defined in most cases by a balanced t(15;17) chromosomal translocation that creates the PML::RARA fusion oncoprotein. This fusion enforces a differentiation block at the promyelocyte stage and is associated with a distinctive, high-risk hemorrhagic/coagulopathic presentation. (iyer2023thetreatmentof pages 1-2, bercier2024historyofdeveloping pages 4-6, gill2023acutepromyelocyticleukaemia pages 1-2)

Common synonyms and alternative names

Commonly used names include acute promyelocytic leukemia, acute promyelocytic leukaemia, APL, FAB AML-M3, and PML-RARα / PML::RARA-positive APL. (almeida2023acutepromyelocyticleukemia pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Key identifiers and classification systems

• ICD-10: C92.4 (acute promyelocytic leukemia) is used in real-world health services research for APL. (guarnera2024acutepromyelocyticleukemialike pages 1-2)
• Molecular hallmark: PML::RARA fusion transcript. (iyer2023thetreatmentof pages 1-2, ghiaur2024acutepromyelocyticleukemia pages 1-2)
• MONDO / Orphanet / OMIM / MeSH: Not directly extractable from the retrieved full-text evidence in this run; therefore not asserted here.

Evidence source type

The available evidence includes (i) aggregated disease-level resources (reviews), (ii) population-based outcomes research (registry/cohort), and (iii) mechanistic primary research (cell/mouse/xenograft models). (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2, dai2023targetinghdac3to pages 1-2)

2. Etiology

Disease causal factors (genetic/mechanistic)

The primary causal lesion in classical APL is the PML::RARA fusion generated by t(15;17), which acts as a dominant-negative regulator of retinoic acid receptor signaling and disrupts PML nuclear bodies, producing a differentiation block. (bercier2024historyofdeveloping pages 4-6, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Risk factors

Robust, population-level external risk factors (environmental/lifestyle) were not identifiable from the retrieved evidence.

However, several studies highlight presentation severity features that act as strong clinical risk factors for early mortality (a major outcome determinant): * Leukocytosis/high WBC is repeatedly linked to higher early death risk in population-based and real-world cohorts. (gill2023acutepromyelocyticleukaemia pages 1-2, iyer2023thetreatmentof pages 2-4) * A real-world cohort focusing on very early death reported associations with DIC score severity and elevated creatinine (independent predictor of 7‑day ED). (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Protective factors

No specific protective genetic or environmental factors were extractable from the retrieved evidence.

Gene–environment interactions

No direct gene–environment interaction evidence was extractable from the retrieved evidence.

3. Phenotypes

Core clinical phenotypes (human clinical)

APL typically presents as an acute leukemia with cytopenias plus a prominent thrombo-hemorrhagic diathesis driven by severe coagulopathy, often described as DIC with hyperfibrinolysis. (iyer2023thetreatmentof pages 1-2, almeida2023acutepromyelocyticleukemia pages 1-2)

Key clinical manifestations and laboratory abnormalities supported by the retrieved evidence: * Coagulopathy / DIC / hyperfibrinolysis → major driver of early death. (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2) * Severe hemorrhage, often intracranial and pulmonary in reports/reviews. (almeida2023acutepromyelocyticleukemia pages 1-2) * Differentiation syndrome (DS) as a treatment complication during differentiation therapy (ATRA/ATO), described as systemic inflammatory/vasoactive syndrome and included among causes of early morbidity/mortality. (iyer2023thetreatmentof pages 2-4, ghiaur2024acutepromyelocyticleukemia pages 1-2) * Typical immunophenotype (supporting diagnosis): commonly CD33+, CD13+, HLA‑DR negative, and often low-frequency CD34 expression. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Phenotype characteristics

• Temporal profile: onset is typically acute/subacute (acute leukemia presentation); early deaths cluster within the first days to 30 days after diagnosis, highlighting the time-critical nature of supportive care and prompt ATRA initiation. (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)
• Frequency/importance: coagulopathy is consistently described as a hallmark feature and leading cause of early death. (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Quality of life impact

Direct QoL instrument results (e.g., EQ‑5D, SF‑36, PROMIS) were not extractable from the retrieved evidence; however, real-world reviews emphasize that early mortality and acute complications can prevent patients from receiving curative therapy, and that treatment toxicities (QT prolongation, hepatic toxicity, neurotoxicity, DS) require close monitoring. (ghiaur2024acutepromyelocyticleukemia pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2)

Suggested HPO terms (examples; mapping suggestions)

• Disseminated intravascular coagulation (HP:0001979)
• Thrombocytopenia (HP:0001873)
• Hemorrhage (HP:0001892) / Intracranial hemorrhage (HP:0002170)
• Hyperfibrinolysis (HP:0003253; if used)
• Leukocytosis (HP:0001974) / Hyperleukocytosis (HP:0001974 with qualifier)
• Acute myeloid leukemia (HP:0004808)
• Differentiation syndrome (not consistently represented as a single HPO term in all releases; may require synonym mapping)

4. Genetic / molecular information

Causal genes and chromosomal abnormalities

• Causal fusion: PML::RARA (PML fused to retinoic acid receptor alpha, RARA) created by t(15;17). (bercier2024historyofdeveloping pages 4-6, iyer2023thetreatmentof pages 1-2)
• Disease definition: the PML::RARA fusion is described as the hallmark/defining lesion and therapeutic target of ATRA and ATO. (ghiaur2024acutepromyelocyticleukemia pages 1-2)

Variant fusions / molecular heterogeneity

Non-canonical RARA fusion partners (often termed “APL-like AML”) are rare but clinically critical because some are less sensitive/insensitive to arsenic-based therapy; a 2024 review summarizes that these entities are diagnostically challenging and heterogeneous. (guarnera2024acutepromyelocyticleukemialike pages 1-2, bercier2024historyofdeveloping pages 6-7)

Somatic co-mutations (modifiers)

A 2024 MRD-focused review notes that co-mutations such as FLT3, WT1, NRAS, KRAS occur and may affect prognosis, supporting broader molecular profiling beyond the fusion transcript in some contexts. (kegyes2024mrdinacute pages 6-7)

Epigenetic / post-translational regulation relevant to therapy response

Primary mechanistic literature and reviews converge on a pathway where ATO binding to the PML moiety drives post-translational modifications (SUMOylation/ubiquitination) leading to fusion degradation: * A 2023 Cell Death & Differentiation study summarizes ATO-induced SUMOylation and ubiquitination of PML‑RARα (including roles for PIAS1 and RNF4) as central to its degradation, and proposes HDAC3 as a modulator of this degradative pathway (via PML‑RARα deacetylation affecting PIAS1-mediated SUMOylation). (dai2023targetinghdac3to pages 1-2) * A 2024 historical/mechanistic review emphasizes that PML nuclear bodies are hubs for post-translational modifications including SUMOylation and ubiquitination and are disrupted by PML‑RARA. (bercier2024historyofdeveloping pages 6-7)

Suggested GO terms (mechanism-related; examples)

• GO:0003700 DNA-binding transcription factor activity (fusion TF behavior)
• GO:0006355 regulation of transcription, DNA-templated (altered transcriptional programs)
• GO:0032182 SUMOylation
• GO:0016567 protein ubiquitination
• GO:0030433 ubiquitin-dependent protein catabolic process
• GO:0006915 apoptosis (ATO dose-dependent apoptosis)
• GO:0030154 cell differentiation (ATRA-induced granulocytic differentiation)

5. Environmental information

No specific environmental or infectious etiologic agents were extractable from the retrieved evidence.

6. Mechanism / pathophysiology

Causal chain (current understanding)

1) Initiating lesion: t(15;17) generates PML::RARA. (bercier2024historyofdeveloping pages 4-6, iyer2023thetreatmentof pages 1-2)
2) Nuclear/transcriptional effects: the fusion represses RARA target gene programs and disrupts PML nuclear bodies, leading to blocked granulocytic differentiation and abnormal promyelocyte accumulation. (guarnera2024acutepromyelocyticleukemialike pages 1-2, bercier2024historyofdeveloping pages 4-6)
3) System-level clinical phenotype: the leukemia has a characteristic coagulopathy/DIC and bleeding phenotype responsible for high early mortality without immediate recognition and treatment. (iyer2023thetreatmentof pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)
4) Therapeutic mechanism (differentiation therapy): ATRA and ATO directly target the molecular lesion and associated nuclear structures: * ATRA relieves PML‑RARA–driven transcriptional repression and promotes terminal differentiation. (bercier2024historyofdeveloping pages 4-6, dai2023targetinghdac3to pages 1-2) * ATO binds the PML component and promotes post-translational modification cascades that drive PML‑RARA degradation and restoration of functional PML nuclear bodies. (dai2023targetinghdac3to pages 1-2, bercier2024historyofdeveloping pages 6-7)

Cellular processes / pathways highlighted by authoritative sources

A 2024 review describing “classic” APL biology states that PML::RARA “represses the transcription of RARa target genes and disrupts PML nuclear bodies, with subsequent impairment of differentiation, self-renewal, and response to DNA damage.” (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Cell types (suggested CL terms)

• Promyelocyte (CL:0000576) — malignant differentiation-arrested population
• Myeloid progenitor cell (e.g., CL:0000763 for myeloid progenitor)
• Granulocyte / neutrophil lineage cells (CL:0000775; mature differentiation outcome)

7. Anatomical structures affected

Primary organs/systems

APL is a hematologic malignancy primarily involving bone marrow and peripheral blood, with secondary system involvement driven by coagulopathy/bleeding (e.g., central nervous system hemorrhage) and treatment complications. (gill2023acutepromyelocyticleukaemia pages 1-2, almeida2023acutepromyelocyticleukemia pages 1-2)

Suggested UBERON terms

• Bone marrow (UBERON:0002371)
• Blood (UBERON:0000178)
• Brain (UBERON:0000955) — relevant due to intracranial hemorrhage emphasis

Subcellular localization

Key disease biology centers on nuclear bodies (PML nuclear bodies) and nuclear transcriptional regulation. (bercier2024historyofdeveloping pages 6-7, guarnera2024acutepromyelocyticleukemialike pages 1-2)

8. Temporal development

Onset and progression

Disease onset is acute, with clinically important outcomes (especially hemorrhagic deaths) occurring early after presentation/diagnosis if ATRA and supportive care are delayed. A treatment review explicitly highlights “high risk of early death without prompt initiation of treatment at first clinical suspicion.” (iyer2023thetreatmentof pages 1-2)

Stages/course

A clinically meaningful “stage-like” construct used in practice is risk stratification by presenting WBC (and historically platelets) (e.g., WBC >10×10^9/L classified as high-risk in many schemas), which correlates with early death risk and guides intensity/adjunctive cytoreduction. (iyer2023thetreatmentof pages 2-4)

9. Inheritance and population

Inheritance pattern

APL (PML::RARA) is a somatic fusion-driven leukemia; germline Mendelian inheritance is not supported by the retrieved evidence.

Epidemiology (incidence; demographic notes)

• Incidence: A population-based study (1991–2021) reported annual incidence averaging 0.32 per 100,000 in its population. (gill2023acutepromyelocyticleukaemia pages 1-2)
• A 2024 review reports APL accounts for 8–15% of AML and cites a European incidence estimate of 0.12 per 100,000 person-years. (guarnera2024acutepromyelocyticleukemialike pages 1-2)
• Age/sex in the population-based cohort: median age 44 years (range 1–97); 374 males/387 females. (gill2023acutepromyelocyticleukaemia pages 1-2)

10. Diagnostics

Diagnostic concept

APL is a time-critical diagnosis because its defining biology creates a high immediate risk of fatal hemorrhage. Molecular confirmation is recommended, but treatment is emphasized as urgent when APL is suspected clinically. (iyer2023thetreatmentof pages 1-2, bercier2024historyofdeveloping pages 4-6)

Clinical/pathology tests

• Morphology: promyelocyte accumulation in blood/marrow; may show Auer rods. (bercier2024historyofdeveloping pages 4-6)
• Flow cytometry phenotype: often CD33+/CD13+, HLA‑DR negative, low-frequency CD34 expression. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Genetic/molecular diagnostics

• RT-PCR / real-time quantitative PCR (RQ-PCR) for detection of the APL-specific PML::RARA lesion is described as a route to rapid molecular confirmation, and is used for MRD monitoring in at least high-risk patients. (bercier2024historyofdeveloping pages 4-6)
• Population-based studies report use of karyotype plus RT-PCR for PML‑RARA for confirmation. (gill2023acutepromyelocyticleukaemia pages 1-2)

MRD (measurable residual disease)

• PCR-based detection of PML‑RARA in remission can anticipate relapse; a 2024 MRD review notes that RT-PCR positivity can precede morphologic relapse by 1–4 months and that “molecular relapse” emerged from this predictive capacity. (kegyes2024mrdinacute pages 6-7)
• A treatment review cautions that “a positive PML‑RARA PCR at count recovery does not necessarily portend resistant disease,” emphasizing interpretation in context of timing/clinical course. (iyer2023thetreatmentof pages 2-4)

11. Outcome / prognosis

Modern curability contrasted with early-death risk

A 2023 treatment review states in its abstract that APL has been transformed into a “highly curable cancer with long-term survival exceeding 90%,” but also emphasizes that early death remains a major risk without rapid therapy. (iyer2023thetreatmentof pages 1-2)

Real-world outcomes and early mortality statistics

• In a population-based cohort (1991–2021), there were 144 early deaths (defined as first 30 days), with early deaths “almost exclusively” occurring in ATRA-based inductions (139/144); overall 5-year and 10-year OS were 68.1% and 63.3%, while post‑30‑day OS was 84.0% and 78.1%. (gill2023acutepromyelocyticleukaemia pages 1-2)
• Real-world observational work on very early death emphasizes the contribution of coagulopathy severity (DIC scores) to deaths before treatment initiation and within the first 7 days. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

12. Treatment

Treatment principles (current standard concept)

APL is the paradigm of molecularly targeted differentiation therapy: all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are directed at the PML::RARA-driven state and have enabled “chemotherapy-free” curative strategies for many patients. (iyer2023thetreatmentof pages 1-2, ghiaur2024acutepromyelocyticleukemia pages 1-2)

A 2024 review of ATRA/ATO complications states that the PML::RARA fusion is the molecular target of ATRA and ATO and that ATRA+ATO achieves “deep and durable molecular responses with a very low incidence of relapse,” while requiring monitoring for DS, hepatotoxicity, QT prolongation, and neurotoxicity. (ghiaur2024acutepromyelocyticleukemia pages 1-2)

Key regimens and reported outcomes (selected evidence-based statistics)

• ATRA- plus oral-ATO-based regimens in a population program: In a 1991–2021 population-based study where oral-ATO-based regimens were implemented from 2013, oral-ATO use was associated with fewer early deaths and superior survival outcomes compared with earlier eras; reported incidence and survival statistics are summarized above. (gill2023acutepromyelocyticleukaemia pages 1-2)
• Chemotherapy-free strategies in all-risk settings: A randomized phase III non-inferiority study reported complete remission 97% in both ATRA‑ATO and ATRA‑ATO+chemotherapy arms; 2‑year DFS 98% vs 97% and EFS 95% vs 92% (all-risk); high-risk subgroup DFS 94% vs 87% and EFS 85% vs 78%. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

Supportive care implications (real-world implementation)

Population-based and real-world reviews emphasize that the gap between trial outcomes and real-world outcomes is largely driven by early mortality, delays in diagnosis/treatment, and variable expertise/resources for managing coagulopathy and complications. (guarnera2024acutepromyelocyticleukemialike pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)

Treatment complications

A dedicated complications review highlights that ATRA/ATO therapy, while less hematologically toxic than chemotherapy, can cause differentiation syndrome, liver toxicity, QT interval prolongation, and neurotoxicity, requiring “rigorous monitoring.” (ghiaur2024acutepromyelocyticleukemia pages 1-2)

Suggested MAXO terms (examples; mapping suggestions)

• All-trans retinoic acid therapy (differentiation therapy)
• Arsenic trioxide therapy
• Combination drug therapy (ATRA + ATO)
• Supportive care for coagulopathy / transfusion support
• Molecular monitoring (PCR-based MRD testing)

13. Prevention

No established primary prevention strategies were extractable from the retrieved evidence, consistent with APL being largely a sporadic, somatic-fusion malignancy. Secondary/tertiary “prevention” in practice centers on early suspicion, immediate ATRA initiation, aggressive management of coagulopathy, and molecular MRD monitoring to detect relapse early. (iyer2023thetreatmentof pages 1-2, kegyes2024mrdinacute pages 6-7)

14. Other species / natural disease

No naturally occurring APL analog in non-human species was identified in the retrieved evidence.

15. Model organisms and experimental systems

Cell line models

Reviews and mechanistic studies reference use of cell lines as core discovery tools to establish dominance of PML‑RARA and to probe response/resistance mechanisms to ATRA/ATO. (bercier2024historyofdeveloping pages 4-6, dai2023targetinghdac3to pages 1-2)

Mouse and xenograft models

• A 2024 review notes that transgenic mouse models expressing PML‑RARA in the myeloid lineage can mimic APL and have been used to show that PML‑RARA can be a solitary initiating oncogenic event in appropriate contexts. (bercier2024historyofdeveloping pages 6-7)
• A 2023 mechanistic paper used patient-derived xenograft (PDX) approaches (including serial transfers) to test how modulating HDAC3 affects PML‑RARα degradation and therapy resistance. (dai2023targetinghdac3to pages 1-2)

Model limitations (from available evidence)

The retrieved evidence does not provide structured limitations analyses; however, the consistent emphasis on early death/coagulopathy as a dominant real-world outcome determinant implies that animal/cell models may incompletely capture the health-system and supportive-care drivers of early mortality.

Expert opinions and authoritative synthesis (2023–2024 prioritized)

Recent authoritative reviews converge on two major points: 1) APL is highly curable in principle with ATRA+ATO-based molecularly targeted therapy (often quoted as >90% long-term survival in contemporary series), making it a flagship of targeted differentiation therapy. (iyer2023thetreatmentof pages 1-2, ghiaur2024acutepromyelocyticleukemia pages 1-2) 2) Early death remains the critical barrier to realizing these cure rates in real-world practice; high-quality supportive care and rapid initiation of ATRA are repeatedly highlighted as key interventions to close the trial–real-world gap. (iyer2023thetreatmentof pages 1-2, guarnera2024acutepromyelocyticleukemialike pages 1-2, gill2023acutepromyelocyticleukaemia pages 1-2)

Key recent statistics (quick list)

• Annual APL incidence average 0.32 per 100,000 in a population study (1991–2021). (gill2023acutepromyelocyticleukaemia pages 1-2)
• APL proportion of AML reported as ~8–15% (review). (guarnera2024acutepromyelocyticleukemialike pages 1-2)
• Early deaths (first 30 days): 144 in a 1991–2021 population cohort; predominantly in ATRA-based induction era. (gill2023acutepromyelocyticleukaemia pages 1-2)
• Overall survival in that cohort: 5-year 68.1%, 10-year 63.3%; post‑30‑day OS: 5-year 84.0%, 10-year 78.1%. (gill2023acutepromyelocyticleukaemia pages 1-2)
• Chemotherapy-free ATRA‑ATO vs ATRA‑ATO+chemotherapy trial: 97% CR in both arms; 2‑year DFS/EFS ~98/95% vs 97/92% (all-risk), and high-risk DFS/EFS 94/85% vs 87/78%. (guarnera2024acutepromyelocyticleukemialike pages 1-2)

References (URLs and publication dates)

The principal sources used in this report are open-access review articles and population-based studies with embedded URLs in citations, including: * Iyer SG et al. Frontiers in Oncology (Jan 2023). https://doi.org/10.3389/fonc.2022.1062524 (iyer2023thetreatmentof pages 1-2, iyer2023thetreatmentof pages 2-4) * Gill H et al. BMC Cancer (Feb 2023). https://doi.org/10.1186/s12885-023-10612-z (gill2023acutepromyelocyticleukaemia pages 1-2) * Bercier P, de Thé H. Cancers (Mar 2024). https://doi.org/10.3390/cancers16071351 (bercier2024historyofdeveloping pages 4-6, bercier2024historyofdeveloping pages 6-7) * Ghiaur A et al. Cancers (Mar 2024). https://doi.org/10.3390/cancers16061160 (ghiaur2024acutepromyelocyticleukemia pages 1-2) * Kegyes D et al. Cancers (Sep 2024). https://doi.org/10.3390/cancers16183208 (kegyes2024mrdinacute pages 6-7) * Guarnera L et al. Cancers (Dec 2024). https://doi.org/10.3390/cancers16244192 (guarnera2024acutepromyelocyticleukemialike pages 1-2) * Dai B et al. Cell Death & Differentiation (Mar 2023). https://doi.org/10.1038/s41418-023-01139-8 (dai2023targetinghdac3to pages 1-2) * de Almeida TD et al. Future Pharmacology (Feb 2023). https://doi.org/10.3390/futurepharmacol3010012 (almeida2023acutepromyelocyticleukemia pages 1-2)

References

1. (iyer2023thetreatmentof pages 1-2): Sunil Girish Iyer, Laila Elias, Michele Stanchina, and Justin Watts. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Frontiers in Oncology, Jan 2023. URL: https://doi.org/10.3389/fonc.2022.1062524, doi:10.3389/fonc.2022.1062524. This article has 70 citations.

2. (guarnera2024acutepromyelocyticleukemialike pages 1-2): Luca Guarnera, Emiliano Fabiani, Giulia Falconi, Giorgia Silvestrini, Maria Luigia Catanoso, Mariadomenica Divona, and Maria Teresa Voso. Acute promyelocytic leukemia-like aml: genetic perspective and clinical implications. Cancers, 16:4192, Dec 2024. URL: https://doi.org/10.3390/cancers16244192, doi:10.3390/cancers16244192. This article has 2 citations.

3. (gill2023acutepromyelocyticleukaemia pages 1-2): Harinder Gill, Radha Raghupathy, Carmen Y.Y. Lee, Yammy Yung, Hiu-Tung Chu, Michael Y. Ni, Xiao Xiao, Francis P. Flores, Rita Yim, Paul Lee, Lynn Chin, Vivian W.K. Li, Lester Au, Wing-Yan Au, Edmond S.K. Ma, Diwakar Mohan, Cyrus Rustam Kumana, and Yok-Lam Kwong. Acute promyelocytic leukaemia: population-based study of epidemiology and outcome with atra and oral-ato from 1991 to 2021. BMC Cancer, Feb 2023. URL: https://doi.org/10.1186/s12885-023-10612-z, doi:10.1186/s12885-023-10612-z. This article has 38 citations and is from a peer-reviewed journal.

4. (almeida2023acutepromyelocyticleukemia pages 1-2): Tâmara Dauare de Almeida, Fernanda Cristina Gontijo Evangelista, and Adriano de Paula Sabino. Acute promyelocytic leukemia (apl): a review of the classic and emerging target therapies towards molecular heterogeneity. Future Pharmacology, 3:162-179, Feb 2023. URL: https://doi.org/10.3390/futurepharmacol3010012, doi:10.3390/futurepharmacol3010012. This article has 10 citations.

5. (bercier2024historyofdeveloping pages 4-6): Pierre Bercier and Hugues de Thé. History of developing acute promyelocytic leukemia treatment and role of promyelocytic leukemia bodies. Cancers, 16:1351, Mar 2024. URL: https://doi.org/10.3390/cancers16071351, doi:10.3390/cancers16071351. This article has 11 citations.

6. (bercier2024historyofdeveloping pages 6-7): Pierre Bercier and Hugues de Thé. History of developing acute promyelocytic leukemia treatment and role of promyelocytic leukemia bodies. Cancers, 16:1351, Mar 2024. URL: https://doi.org/10.3390/cancers16071351, doi:10.3390/cancers16071351. This article has 11 citations.

7. (ghiaur2024acutepromyelocyticleukemia pages 1-2): Alexandra Ghiaur, Cristina Doran, Mihnea-Alexandru Gaman, Bogdan Ionescu, Aurelia Tatic, Mihaela Cirstea, Maria Camelia Stancioaica, Roxana Hirjan, and Daniel Coriu. Acute promyelocytic leukemia: review of complications related to all-trans retinoic acid and arsenic trioxide therapy. Cancers, 16:1160, Mar 2024. URL: https://doi.org/10.3390/cancers16061160, doi:10.3390/cancers16061160. This article has 17 citations.

8. (iyer2023thetreatmentof pages 2-4): Sunil Girish Iyer, Laila Elias, Michele Stanchina, and Justin Watts. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Frontiers in Oncology, Jan 2023. URL: https://doi.org/10.3389/fonc.2022.1062524, doi:10.3389/fonc.2022.1062524. This article has 70 citations.

9. (dai2023targetinghdac3to pages 1-2): Bo Dai, Feng Wang, Ying Wang, Jiayan Zhu, Yunxuan Li, Tingting Zhang, Lu Zhao, Li-Ling Wang, Wen-hui Gao, Jun Yu Li, A. Liang, Hongming Zhu, Ke Li, and Jiong Hu. Targeting hdac3 to overcome the resistance to atra or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of pml-rarα. Cell Death & Differentiation, 30:1320-1333, Mar 2023. URL: https://doi.org/10.1038/s41418-023-01139-8, doi:10.1038/s41418-023-01139-8. This article has 33 citations and is from a domain leading peer-reviewed journal.

10. (kegyes2024mrdinacute pages 6-7): David Kegyes, Praveena S. Thiagarajan, and Gabriel Ghiaur. Mrd in acute leukemias: lessons learned from acute promyelocytic leukemia. Cancers, Sep 2024. URL: https://doi.org/10.3390/cancers16183208, doi:10.3390/cancers16183208. This article has 3 citations.